Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViiV Says Latest Data Back Two-Drug Approach, Plans Year-End Fostemsavir Filing

Executive Summary

ViiV Healthcare research head tells Scrip she expects Dovato’s latest data presentation should boost the two-drug regimen’s uptake, and that the AIDS-fighter plans a US FDA filing of its investigational candidate fostemsavir before end-2019 following good Phase III BRIGHTE results.

You may also be interested in...



Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

ViiV Seeks Speedy EMA Review For Last-Resort HIV Drug

ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.

A Switch To ViiV's Two-Drug Dovato Keeps HIV Suppressed

Top-line results from the Phase III TANGO study suggests that switching to ViiV’s two-drug Dovato from a three-drug regimen does not affect the efficacy of treatment.

Topics

Related Companies

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel